- Markets
- Healthcare
- GUJTHEM
GUJTHEM
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Gujarat Themis Biosyn Appoints Bhavik Shah As CFO
Feb 14 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
GUJARAT THEMIS BIOSYN LTD - APPOINTS BHAVIK SHAH AS CFO
Source text: ID:nBSE5q7g9f
Further company coverage: GTHM.BO
(([email protected];))
Feb 14 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
GUJARAT THEMIS BIOSYN LTD - APPOINTS BHAVIK SHAH AS CFO
Source text: ID:nBSE5q7g9f
Further company coverage: GTHM.BO
(([email protected];))
Gujarat Themis Biosyn CFO Bharat Desai To Retire
Oct 25 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
BHARAT DESAI TO RETIRE AS CFO EFFECTIVE 31 DECEMBER 2024
APPOINTS BHAVIK SHAH AS INTERIM CFO
Source text for Eikon: ID:nBSEK7y2t
Further company coverage: GTHM.BO
(([email protected];))
Oct 25 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
BHARAT DESAI TO RETIRE AS CFO EFFECTIVE 31 DECEMBER 2024
APPOINTS BHAVIK SHAH AS INTERIM CFO
Source text for Eikon: ID:nBSEK7y2t
Further company coverage: GTHM.BO
(([email protected];))
Gujarat Themis Biosyn Approved Issue Of 1 Bonus Share For Every 2 Shares
May 14 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
APPROVED ISSUE OF 1 BONUS SHARE FOR EVERY 2 SHARES
Source text for Eikon: ID:nBSE8JV51D
Further company coverage: GTHM.BO
(([email protected];))
May 14 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
APPROVED ISSUE OF 1 BONUS SHARE FOR EVERY 2 SHARES
Source text for Eikon: ID:nBSE8JV51D
Further company coverage: GTHM.BO
(([email protected];))
Gujarat Themis Biosyn To Consider Proposal Of Sub-Division Of Shares
May 4 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
TO CONSIDER PROPOSAL OF SUB-DIVISION OF SHARES
Source text for Eikon: ID:nBSE8BJnQy
Further company coverage: GTHM.BO
(([email protected];))
May 4 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
TO CONSIDER PROPOSAL OF SUB-DIVISION OF SHARES
Source text for Eikon: ID:nBSE8BJnQy
Further company coverage: GTHM.BO
(([email protected];))
Events:
Bonus
Dividend
Dividend
Split
Dividend
Dividend
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Guj. Themis Biosyn do?
Global Trust Bank Limited, a joint sector company, originally producing Erythromycin, was taken over by Pharmaceutical Business Group (India) Ltd. The company later entered collaboration with Yuhan Corporation to produce Rifampicin, becoming India's first to do so.
Who are the competitors of Guj. Themis Biosyn?
Guj. Themis Biosyn major competitors are Concord Biotech, Medicamen Biotech, Gufic Biosciences, Sequent Scientific, Panacea Biotec, Orchid Pharma, Zota Health Care. Market Cap of Guj. Themis Biosyn is ₹3,321 Crs. While the median market cap of its peers are ₹3,467 Crs.
Is Guj. Themis Biosyn financially stable compared to its competitors?
Guj. Themis Biosyn seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Guj. Themis Biosyn pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Guj. Themis Biosyn latest dividend payout ratio is 12.28% and 3yr average dividend payout ratio is 20.82%
How has Guj. Themis Biosyn allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress
How strong is Guj. Themis Biosyn balance sheet?
Balance sheet of Guj. Themis Biosyn is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Guj. Themis Biosyn improving?
The profit is oscillating. The profit of Guj. Themis Biosyn is ₹52.66 Crs for TTM, ₹59.16 Crs for Mar 2024 and ₹57.97 Crs for Mar 2023.
Is the debt of Guj. Themis Biosyn increasing or decreasing?
Yes, The debt of Guj. Themis Biosyn is increasing. Latest debt of Guj. Themis Biosyn is -₹8.74 Crs as of Sep-24. This is greater than Mar-24 when it was -₹16.31 Crs.
Is Guj. Themis Biosyn stock expensive?
Yes, Guj. Themis Biosyn is expensive. Latest PE of Guj. Themis Biosyn is 63.07, while 3 year average PE is 28.88. Also latest EV/EBITDA of Guj. Themis Biosyn is 44.92 while 3yr average is 21.27.
Has the share price of Guj. Themis Biosyn grown faster than its competition?
Guj. Themis Biosyn has given lower returns compared to its competitors. Guj. Themis Biosyn has grown at ~13.8% over the last 1yrs while peers have grown at a median rate of 16.12%
Is the promoter bullish about Guj. Themis Biosyn?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Guj. Themis Biosyn is 70.86% and last quarter promoter holding is 70.86%.
Are mutual funds buying/selling Guj. Themis Biosyn?
The mutual fund holding of Guj. Themis Biosyn is stable. The current mutual fund holding in Guj. Themis Biosyn is 1.16% while previous quarter holding is 1.16%.